59 Belagenpumatucel-L, an allogeneic genetically modified NSCLC tumor cell vaccine, showed a trend toward increased median survival but this did not reach statistical significance. 53 However, the subgroup of patients who received vaccination within 12 weeks of chemotherapy had a statistically significant improvement, and the study is continuing in this subgroup of patients.
← all excerpts
Therapeutic cancer vaccines and combination immunotherapies involving vaccination.
1
—
—